Abbott Laboratories beat expectations with a quarterly profit thanks to strong medical device sales.
Sales of glucose monitoring products were particularly strong.
An increase in demand for medical interventions supported overall growth.
Annual earnings of 98 cents per share beat analysts' estimates by 3 cents.
Abbott Laboratories $ABT raised its full-year forecast to $4.55 to $4...
Read more
Currently I can think of only two Israeli companies Mobileye and Teva and I don't see any big drop there. The Israeli stock market has also behaved normally in price, so it will probably depend on how the conflict escalates.